Antitumor activity and pharmacokinetic properties of ARS-interacting multi-functional protein 1 (AIMP1/p43)

Cancer Letters

Volumn 287, Issue 2, 2010, Pages 157-164

  Han, Jung Min ^a   Myung, Heejoon ^b   Kim, Sunghoon ^a  

^a Seoul National University   (South Korea)

^b Hankuk University of Foreign Studies   (South Korea)

Author keywords

AIMP1; Angiogenesis; Antitumor; Cytokine; Human xenograft mouse; Inflammation; Pharmacokinetics

Indexed keywords

ANTINEOPLASTIC AGENT; ARS INTERACTING MULTIFUNCTIONAL PROTEIN 1; FLUOROURACIL; INTERLEUKIN 1BETA; PACLITAXEL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER TISSUE; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG HALF LIFE; DRUG STABILITY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SINGLE DRUG DOSE; STOMACH CANCER; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BODY WEIGHT; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DOGS; DRUG STABILITY; HALF-LIFE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; PROLIFERATING CELL NUCLEAR ANTIGEN; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RNA-BINDING PROTEINS; STOMACH NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

CANIS FAMILIARIS; MUS; RATTUS;

EID: 72949092901     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.06.005     Document Type: Article

References (28)

1. Quevillon S., Agou F., Robinson J.C., and Mirande M. The p43 component of the mammalian multi-synthetase complex is likely to be the precursor of the endothelial monocyte-activating polypeptide II cytokine. J. Biol. Chem. 272 (1997) 32573-32579
2. Ko Y.G., Park H., Kim T., Lee J.W., Park S.G., Seol W., Kim J.E., Lee W., Kim S., Park J., and Kim S. A cofactor of tRNA synthetase, p43, is secreted to upregulate proinflammatory genes. J. Biol. Chem. 276 (2001) 23028-23033
3. Park S.G., Kang Y.S., Ahn Y.H., Lee S.H., Kim K.R., Kim K., Koh G.Y., Ko Y., and Kim S. Dose-dependent biphasic activity of tRNA synthetase associating factor, p43, in angiogenesis. J. Biol. Chem. 277 (2002) 45243-45248
4. Park S.G., Shin H., Shin Y.K., Lee Y., Choi E.C., Park B., and Kim S. The novel cytokine p43 stimulates dermal fibroblast proliferation and wound repair. Am. J. Pathol. 166 (2005) 387-398
5. Park S.G., Kang Y.S., Kim J.Y., Lee C.S., Ko Y.G., Lee W.J., Lee K.-U., Ueom Y.I., and Kim S. Hormonal activity of AIMP1/p43 for glucose homeostasis. Proc. Nat. Acad. Sci. USA 103 (2006) 14913-14918
6. Folkman J. Tumor angiogenesis: therapeutic implications. New. Engl. J. Med. 285 (1971) 1182-1186
7. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 438 (2005) 932-936
8. Tabruyn S.P., and Griffioen A.W. Molecular pathways of angiogenesis inhibition. Biochem. Biophys. Res. Commun. 355 (2007) 1-5
9. Manda T., Nishigaki F., Mori J., and Shimomura K. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity. Cancer Res. 47 (1987) 3707-3711
10. Apte R.N., Dotan S., Elkabets M., White M.R., Reich E., Carmi Y., Song X., Dvozkin T., Krelin Y., and Voronov E. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metast. Rev. 25 (2006) 387-408
11. Del Vecchio M., Bajetta E., Canova S., Lotze M.T., Wesa A., Parmiani G., and Anichini A. Interleukin-12: Biological properties and clinical application. Clin. Cancer Res. 13 (2007) 4677-4685
12. Boost K.A., Sadik C.D., Bachmann M., Zwissler B., Pfeilschifter J., and Mühl H. IFN-gamma impairs release of IL-8 by IL-1 beta-stimulated A549 lung carcinoma cells. BMC Cancer 8 (2008) 265-272
13. Lee Y.-S., Han J.M., Kang T., Park Y.I., Kim H.M., and Kim S. Antitumor activity of novel human cytokine AIMP1 in an in vivo tumor model. Mol. Cells 21 (2006) 299-315
14. Daniel D., and Wilson N.S. Tumor necrosis factor: renaissance as a cancer therapeutic?. Curr. Cancer Drug Targets 8 (2008) 124-131
15. ten Hagen T.L.M., Seynhaeve A.L.B., and Eggermont A.M.M. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol. Rev. 222 (2008) 299-315
16. Markmann M. What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?. Int. J. Gynecol. Cancer 18 Suppl. 1 (2008) 36-39
17. Lans T.E., ten Hagen T.L., van Horssen R., Wu P.C., van Tiel S.T., Libutti S.K., Alexander H.R., and Eggermont A.M. Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma. Ann. Surg. Oncol. 9 (2002) 812-819
18. Lans T.E., van Horssen R., Eggermont A.M., and ten Hagen T.L. Involvement of endothelial monocyte activating polypeptide II in tumor necrosis factor-alpha-based anti-cancer therapy. Anticancer Res. 24 (2004) 2243-2248
19. van Horssen R., Rens J.A.P., Brunstein F., Guns V., van Gils M., ten Hagen T.L.M., and Eggermont A.M.M. Intratumoural expression of TNF-R1 and EMAP-II in relation to response of patients treated with TNF-based isolated limb perfusion. Int. J. Cancer 119 (2006) 1481-1490
20. van Horssen R., Rens J.A.P., Schipper D., Eggermont A.M.M., and ten Hagen T.L.M. EMAP-II facilitates TNF-R1 apoptotic signalling in endothelial cells and induces TRADD mobilization. Apoptosis 11 (2006) 2137-2145
21. Yoshikawa T., Yanoma S., Tsuburaya A., Kobayashi O., Sairenji M., Motohashi H., and Noguchi Y. Angiogenesis inhibitor, TNP-470, suppresses growth of peritoneal disseminating foci. Hepatogastroenterology 47 (2000) 298-302
22. Dang D.T., Chun S.Y., Burkitt K., Abe M., Chen S., Havre P., Mabjeesh N.J., Heath E.I., Vogelzang N.J., Cruz-Correa M., Blayney D.W., Ensminger W.D., Croix B.St., Dang N.H., and Dang L.H. Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition. Cancer Res. 68 (2008) 1872-1880
23. Gabizon A., Catane R., Uziely B., Kaufman B., Safra T., Cohen R., Martin F., Huang A., and Barenholz Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 54 (1994) 987-992
24. Dvorak H.F., Brown L.F., Detmar M., and Dvorak A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146 (1995) 1029-1039
25. Allen T.M. Liposomes: opportunities in drug delivery. Drugs 54 (1997) 8-14
26. Gabizon A., and Martin F. Polyethylene glycol coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumors. Drugs 54 (1997) 15-21
27. Bellone M., Mondino A., and Corti A. Vascular targeting, chemotherapy and active immunotherapy: teaming up to attack cancer. Trends Immunol. 29 (2008) 235-241
28. Tandle A., Hanna E., Lorang D., Hajitou A., Moya C.A., Pasqualini R., Arap W., Adem A., Starker E., Hewitt S., and Libutti S.K. Tumor vasculature-targeted delivery of tumor necrosis factor-α. Cancer 1 (2009) 128-139